Clinical trial
Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
NCT00354068 · Duke University, Other · Completed
Key facts
| NCT number | NCT00354068 |
|---|---|
| Title | Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma |
| Official title | A Phase I Study of Imatinib Mesylate in Combination With Temozolomide in Patients With Malignant Glioma |
| Lead sponsor | Duke University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug, Other |
| Interventions | imatinib mesylate, temozolomide, pharmacological study |
| Enrollment | 65 |
| Start date | Jul 1, 2004 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Jul 20, 2006 |
| Last update posted | Mar 28, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: